Journal
LABORATORY INVESTIGATION
Volume 95, Issue 1, Pages 26-42Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/labinvest.2014.132
Keywords
-
Categories
Funding
- Ministry of Science and Technology of Taiwan [102-2120-M-008-002, 102-2221-E-008-112-MY2]
- LandSeed Hospital project [NCU-LSH-101-A-001, NCU-LSH-102-A-003]
- National Defense Medical Center Project [102NCU-NDMC-01]
- Cathay General Hospital Project [101CGH-NCU-A2, 102NCU-CGH-02, CGH-MR-10115, CGH-MR-A10204]
- Ministry of Education, Culture, Sports, Science, and Technology of Japan [24560968]
- Grants-in-Aid for Scientific Research [15K06591, 24560968] Funding Source: KAKEN
Ask authors/readers for more resources
Induced pluripotent stem cells (iPSCs) provide a platform to obtain patient-specific cells for use as a cell source in regenerative medicine. Although iPSCs do not have the ethical concerns of embryonic stem cells, iPSCs have not been widely used in clinical applications, as they are generated by gene transduction. Recently, iPSCs have been generated without the use of genetic material. For example, protein-induced PSCs and chemically induced PSCs have been generated by the use of small and large (protein) molecules. Several epigenetic characteristics are important for cell differentiation; therefore, several small-molecule inhibitors of epigenetic-modifying enzymes, such as DNA methyltransferases, histone deacetylases, histone methyltransferases, and histone demethylases, are potential candidates for the reprogramming of somatic cells into iPSCs. In this review, we discuss what types of small chemical or large (protein) molecules could be used to replace the viral transduction of genes and/or genetic reprogramming to obtain human iPSCs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available